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Abstract
Background: The vanilloid receptor 1 (TRPV1) is critical in the development of inflammatory
hyperalgesia. Several receptors including G-protein coupled prostaglandin receptors have been
reported to functionally interact with the TRPV1 through a cAMP-dependent protein kinase A
(PKA) pathway to potentiate TRPV1-mediated capsaicin responses. Such regulation may have
significance in inflammatory pain. However, few functional receptor interactions that inhibit PKA-
mediated potentiation of TRPV1 responses have been described.
Results: In the present studies we investigated the hypothesis that the μ opioid receptor (MOP)
agonist morphine can modulate forskolin-potentiated capsaicin responses through a cAMP-
dependent PKA pathway. HEK293 cells were stably transfected with TRPV1 and MOP, and calcium
(Ca2+) responses to injection of the TRPV1 agonist capsaicin were monitored in Fluo-3-loaded
cells. Pre-treatment with morphine did not inhibit unpotentiated capsaicin-induced Ca2+ responses
but significantly altered capsaicin responses potentiated by forskolin. TRPV1-mediated Ca2+
responses potentiated by the direct PKA activator 8-Br-cAMP and the PKC activator Phorbol-12-
myristate-13-acetatewere not modulated by morphine.
Immunohistochemical studies confirmed that the TRPV1 and MOP are co-expressed on cultured
Dorsal Root Ganglion neurones, pointing towards the existence of a functional relationship
between the G-protein coupled MOP and nociceptive TRPV1.
Conclusion: The results presented here indicate that the opioid receptor agonist morphine acts
via inhibition of adenylate cyclase to inhibit PKA-potentiated TRPV1 responses. Targeting of
peripheral opioid receptors may therefore have therapeutic potential as an intervention to prevent
potentiation of TRPV1 responses through the PKA pathway in inflammation.
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Background
Peripheral sensitization can contribute to the develop-
ment of persistent pain and involves numerous cellular
processes. An important receptor in this process is the
vanilloid receptor 1 or TRPV1. The TRPV1 is a nociceptive
calcium (Ca2+) channel that is activated by capsaicin, the
pungent constituent of chilli peppers, as well as protons
and heat [1]. The TRPV1 is mainly expressed on nocicep-
tive peripheral neurones and appears to be critical in the
development of inflammatory hyperalgesia [1,2], as
axonal transport of TRPV1 mRNA as well as TRPV1 pro-
tein expression are significantly increased in inflamed tis-
sues [3,4], while mice lacking the TRPV1 develop less
thermal hyperalgesia [2] and TRPV1 antagonists reversed
thermal hyperalgesia in inflammation [5].
Phosphorylation of the TRPV1 by numerous kinases,
including cAMP-dependent protein kinase A (PKA), can
regulate function of the receptor [6-8]. cAMP levels are
elevated in inflamed tissues [9,10] and the cAMP/PKA
pathway appears to be essential in sensitizing inflamma-
tory nociception and contributes to the development of
inflammatory hyperalgesia induced by proinflammatory
mediators such as prostaglandin E2 (PGE2) [9,11]. In line
with reported sensitization of the TRPV1 in such inflam-
matory conditions [3,4], PKA-mediated phosphorylation
of the TRPV1 occurs in neurones as well as heterologous
expression systems treated with adenylate cyclase activa-
tors such as forskolin, or direct PKA activators such as 8-
Br-cAMP; while PKA is also involved in PGE2- and anan-
damide-mediated TRPV1 sensitization as well as potenti-
ation of capsaicin responses through the metabotropic
glutamate receptor 5 [6,7,12-17]. Although sensitization
of TRPV1 responses is important, the concept of prevent-
ing sensitization may also be important in modulating
signalling through the TRPV1. However, few studies have
investigated pathways that interact with the TRPV1 to pre-
vent sensitization [12,14].
As a prototypical G-protein coupled receptor that pro-
duces analgesic effects upon activation [18], one such
potential modulator is the μ opioid receptor or MOP.
Direct G-protein coupled effects of opioid receptors
include activation of inwardly rectifying potassium chan-
nels, inhibition of voltage-dependent Ca2+ channels as
well as inhibition of adenylate cyclase [18]. The present
study describes the potential role of opioids, in particular
the MOP agonist morphine, as modulators of TRPV1
responses by utilizing a HEK293 (human embryonic kid-
ney) cell line stably expressing both TRPV1 and MOP and
assesses the possible role of PKA in this modulation. Mor-
phine did not affect unpotentiated TRPV1 responses nor
TRPV1 responses potentiated by the direct PKA activator
8-Br-cAMP or the protein kinase C (PKC) activator Phor-
bol-12-myristate-13-acetate. However, TRPV1 responses
potentiated by forskolin were modulated by morphine,
highlighting the potential for endogenous opioid modu-
lation of TRPV1 responses potentiated by the PKA path-
way in inflammation.
Results
FLAG-MOP/TRPV1 double stable HEK293 cells express 
functional TRPV1 and MOP
Receptor mRNA for both TRPV1 and FLAG-MOP was
effectively translated to receptor protein as Western Blot
analysis showed bands of the expected sizes for both
receptors (Figure 1A and 1B). Two different colonies of
FLAG-MOP/TRPV1 double stable HEK293 cells, colony
13 and colony 21, were selected for functional studies
based on their expression of TRPV1 and FLAG-MOP pro-
tein (Figure 1A and 1B, lanes 1 and 2) and capsaicin
responses (Figure 2). For both FLAG-MOP/TRPV1 colo-
nies, the TRPV1 was present in two forms; a non-glyco-
sylated form with a corresponding band at approximately
95 kDa, and a glycosylated form with a predicted molecu-
lar weight of 113 kDa (Figure 1A, lanes 1 and 2). Colony
13 (Figure 1A, lane 1) expressed slightly more TRPV1 than
colony 21 (Figure 1A, lane 2) while no TRPV1 protein was
detected in either untransfected HEK293 cells (Figure 1A,
lane 3) or HEK293 cells that were transfected with FLAG-
MOP only (Figure 1A, lane 4). Colonies 13 and 21 were
selected for functional studies as they responded repro-
ducibly to stimulation with capsaicin as described below
(Figure 2). Untransfected HEK cells did not respond to
stimulation with capsaicin (10 μM) (ΔF/F 0.010 ±
0.0015).
Colony 13 (Figure 1B, lane 1), colony 21 (Figure 1B, lane
2) as well as HEK293 cells transfected with FLAG-MOP
only (Figure 2B, lane 3) showed a protein band at approx-
imately 60 kDa, representative of numerous glycosylated
forms of the MOP. Non-transfected HEK293 cells lacked
this band (Figure 1B, lane 4). TRPV1 and MOP expression
were also confirmed using immunohistochemistry with
the overlay (Figure 1C, yellow) clearly demonstrating co-
expression of the MOP (Figure 1D, green) and TRPV1
(Figure 1E, red). Non-specific binding is represented in
Figures 1F and 1G for TRPV1 and MOP, respectively.
To assess functionality of the TRPV1 in the double stable
cell lines, Ca2+ responses to capsaicin were recorded. Both
colonies 13 and 21 responded with concentration-
dependent increases in intracellular free Ca2+ to capsaicin
(Figure 2). EC50s of approximately 34 nM and 40 nM
were determined for colonies 13 and 21, respectively, sim-
ilar to previous studies in TRPV1-transfected HEK293 cell
lines [19-21]. The response to capsaicin was mediated
through activation of the TRPV1, as the TRPV1 antagonist
capsazepine (10 μM; Sigma) inhibited capsaicinMolecular Pain 2006, 2:22 http://www.molecularpain.com/content/2/1/22
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responses to 6.4 ± 2.5% of the control response at 60 sec-
onds.
Morphine inhibits FSK-stimulated cAMP production in 
stable FLAG-MOP/TRPV1 HEK293 cell lines
Functionality of the FLAG-MOP was confirmed using a
cAMP accumulation assay, which assesses functional cou-
pling of the MOP to Gi proteins [18]. Incubation with the
phosphodiesterase inhibitor IBMX (100 μM) and the ade-
nylate cyclase activator FSK (50 μM) significantly (p  <
0.01) increased intracellular cAMP levels in both FLAG-
MOP/TRPV1 colonies (Figure 3, vehicle) compared to
untreated cells (Figure 3, no FSK). As expected, the MOP
agonist morphine (1 μM) significantly (p < 0.01) inhib-
ited the FSK-induced increased in cAMP production by
67.0 ± 4.6% for colony 13 and 79.2 ± 7.4% for colony 21,
although cAMP levels were not reduced to unstimulated
levels (Figure 3, morphine).
FLAG-MOP/TRPV1 double stable HEK293 cells express TRPV1 and MOP Figure 1
FLAG-MOP/TRPV1 double stable HEK293 cells express TRPV1 and MOP. (A) Western Blot Analysis of TRPV1 expression 
from HEK293 cells stably expressing TRPV1 and FLAG-tagged MOP. Precipitated cell proteins were subjected to SDS PAGE 
on a 7.5% gel, transferred to nitrocellulose membrane and probed for TRPV1 expression using a N-terminal directed TRPV1 
antibody. β-actin was used as a loading control. Expected bands for the TRPV1 are at approximately 95 kDa for the unglyco-
sylated and 113 kDa for the glycosylated receptor. Lane 1: Colony 13 FLAG-MOP/TRPV1 double expressant; Lane 2: Colony 
21 FLAG-MOP/TRPV1 double expressant; Lane 3: untransfected HEK293 cells; Lane 4: FLAG-MOP only transfected HEK293 
cells. (B) Western Blot showing FLAG-MOP protein in the same FLAG-MOP/TRPV1 and FLAG-MOP only cells, determined 
using an anti-FLAG M2 antibody. Expected protein size was a broad band at approximately 60 kDa representing multiple glyoc-
sylated FLAG-MOP species. Lane 1: Colony 13 FLAG-MOP/TRPV1 double expressant; Lane 2: Colony 21 FLAG-MOP/TRPV1 
double expressant; Lane 3: FLAG-MOP only transfected HEK293 cells; Lane 4: untransfected HEK293 cells. Representative 
blots from at least 3 independent experiments are presented. (C–E) FLAG-MOP/TRPV1 cells co-express TRPV1 and FLAG-
MOP. Double stable FLAG-MOP/TRPV1 cells were stained for FLAG-MOP (D, green) and TRPV1 (E, red) expression with the 
overlay (C, yellow) clearly demonstrating co-expression of the two receptors. Specificity of the antibodies used was demon-
strated by lack of non-specific binding (F, red and G, green). Scale bar, 40 μm.Molecular Pain 2006, 2:22 http://www.molecularpain.com/content/2/1/22
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Morphine reduces TRPV1-mediated capsaicin-induced 
Ca2+ in the presence of FSK through activation of MOP
We examined whether morphine can inhibit TRPV1-
mediated increases in intracellular free Ca2+ under basal
conditions and with prior sensitization of TRPV1. To
identify if cAMP is a potentiator of TRPV1 responses in
our heterologous expression system, FLAG-MOP/TRPV1
transfected HEK293 cells were pre-incubated with varying
concentrations of FSK as well as a constant concentration
of IBMX (100 μM) and the Ca2+ response to 300 nM cap-
saicin was determined (Figure 4). FSK activates adenylate
cyclase, which in turn increases cellular cAMP levels, thus,
FSK indirectly activates cAMP-dependent PKA. Pre-incu-
bation with vehicle (DMSO) had no effect on Ca2+
responses of colonies 13 (Figure 4A and 4B) and 21 (Fig-
ure 4C and 4D) to 300 nM capsaicin but increasing FSK
concentrations potentiated capsaicin responses in a con-
centration-dependent manner (Figure 4A–D). Injection of
FSK (50 μM) and IBMX (100 μM) caused a small (ΔF/F
0.0152 ± 0.0011) addition response that returned to base-
line after approximately 3 s. This response was not
affected (p > 0.05) by pre-incubation with morphine (1
μM) (p > 0.05; ΔF/F 0.0144 ± 0.0013).
Having identified that FSK potentiates TRPV1 responses in
our heterologous expression system, we assessed whether
morphine inhibits basal or FSK-potentiated TRPV1
responses to capsaicin. This was determined using Fluo-3
loaded FLAG-MOP/TRPV1 HEK293 colonies pre-incu-
bated for 15 min with morphine (1 μM) for opioid-
treated cells or PSS for non-opioid treated cells, followed
by 15 min pre-incubation with FSK (50 μM) and IBMX
(100 μM) for stimulated cells or PSS for unstimulated
cells. Ca2+ responses after injection of various capsaicin
concentrations were monitored for 45 s. Pre-incubation of
FLAG-MOP/TRPV1 colonies with morphine concentra-
tions shown to be effective at reducing cAMP accumula-
tion (Figure 3) did not affect the capsaicin dose-response
curve for colonies 13 and 21 for unstimulated responses
(p > 0.05; Figure 5A,B,D and 5E). However, pre-incuba-
tion with morphine significantly altered the capsaicin
dose-response curve in FSK/IBMX stimulated cells (p  <
0.05; Figure 5).
The inhibition of FSK-stimulated capsaicin (300 nM)
responses by morphine occurred through a MOP-specific
pathway as the opioid receptor antagonist naloxone (50
μM) blocked inhibition by morphine (1 μM) (p < 0.05
compared to FSK+morphine and p > 0.05 compared to
FSK; Figure 6A).
Since morphine-inhibition of FSK-stimulated capsaicin
responses could be due to a reduction in cAMP level
induced by treatment with opioid agonist, we assessed
whether pre-incubation with morphine was required to
achieve modulation of FSK-potentiated capsaicin
responses. To do this, 300 nM capsaicin alone or 300 nM
capsaicin with morphine (final well concentration of 1
Capsaicin dose-response curves from two independent FLAG-MOP/TRPV1 expressants Figure 2
Capsaicin dose-response curves from two independent FLAG-MOP/TRPV1 expressants. Ca2+ responses of Fluo-3-loaded cells 
to injection of capsaicin were measured using a fluorescent Microplate reader and maximum change in fluorescence, expressed 
as ΔF/F, was plotted as a function of capsaicin concentration. A 4-parameter Hill function was fitted to the data using GraphPad 
Prism (San Diego, California). (A) Capsaicin dose-response from FLAG-MOP/TRPV1 double expressant colony 13 (■). (B) 
Capsaicin dose-response from FLAG-MOP/TRPV1 double expressant colony 21 (). Data are expressed as mean ± SEM with 
n = 8.Molecular Pain 2006, 2:22 http://www.molecularpain.com/content/2/1/22
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μM) in cells were added to FLAG-MOP/TRPV1 HEK293
cells pre-incubated with FSK (50 μM) and IBMX (100
μM). Pre-incubation with morphine was required to
achieve inhibition of FSK-stimulated capsaicin responses,
as co-injection of morphine (1 μM) and capsaicin did not
change the Ca2+ response of FLAG-MOP/TRPV1 cells to
300 nM capsaicin (p > 0.05; Figure 6B).
Morphine does not inhibit capsaicin responses potentiated 
by 8-Br-cAMP
FSK is an indirect PKA activator, as it stimulates adenylate
cyclase, which in turn leads to an increase in cellular
cAMP levels, which activates cAMP-dependent PKA [13].
Several papers have reported potentiation or sensitization
of TRPV1 responses through PKA-dependent pathways,
including by treatment with indirect PKA activators like
FSK or direct PKA activators such as 8-Br-cAMP [6,7,13].
The MOP is negatively coupled to adenylate cyclase and
can inhibit FSK-stimulated cAMP production but would
not affect direct PKA activators such as 8-Br-cAMP. To
determine whether morphine-inhibition of FSK-stimu-
lated capsaicin response relies on indirect inhibition of
PKA through a decrease of cAMP levels, FLAG-MOP/
TRPV1 double stable HEK293 cells were pre-incubated for
15 min with varying concentrations of 8-Br-cAMP as well
as constant IBMX concentrations (100 μM) and Ca2+
responses to 300 nM capsaicin were monitored (Figure
7A). Pre-incubation of FLAG-MOP/TRPV1 double expres-
sants with 8-Br-cAMP (300 μM) and IBMX (100 μM)
potentiated Ca2+ responses to 300 nM capsaicin (Figure
7A &7B) in a manner that was dependent on 8-Br-cAMP
concentration, as pre-incubation with IBMX alone did not
significantly affect capsaicin responses (ΔF/F capsaicin
0.116 ± 0.004; ΔF/F capsaicin +IBMX 0.125 ± 0.003; p >
0.05).
Pre-incubation for 15 min with morphine (1 μM) did not
(p > 0.05) affect Ca2+ responses to injection of 300 nM
capsaicin potentiated by 15 min pre-incubation with 8-Br-
cAMP (300 μM) and IBMX (100 μM) (Figure 7B), suggest-
ing that morphine inhibits FSK-potentiated capsaicin
responses by indirectly inhibiting cAMP-dependent PKA.
Morphine does not inhibit capsaicin responses potentiated 
by PMA
Several papers have reported potentiation of TRPV1
responses through PKC-mediated pathways [16,22,23],
and PKC-potentiated TRPV1 responses have been shown
to contribute to diabetic neuropathy [24]. Thus, in order
to determine whether morphine can inhibit TRPV1
responses potentiated by other kinase pathways, we
assessed inhibition of capsaicin responses by the PKC acti-
vator PMA.
Treatment with PMA (100 nM) significantly (p < 0.05)
potentiated TRPV1-mediated capsaicin responses. MOP
function, assessed by morphine inhibition of cAMP accu-
mulation, was preserved in the presence of PMA (data not
shown). Injection of PMA (10 μM) did not cause a Ca2+
responses in FLAG-MOP/TRPV1 expressants (ΔF/F PSS
0.012 ± 0.004; ΔF/F PMA (10 μM) 0.016 ± 0.002; p >
0.05).
Pre-incubation for 15 min with morphine (1 μM) did not
(p > 0.05) affect Ca2+ responses to injection of 30 nM cap-
saicin potentiated by 10 min pre-incubation with PMA
(100 nM) (Figure 7C).
TRPV1 and MOP are co-expressed in cultured DRG 
neurones
To determine if a population of DRG neurons co-
expressed MOP and TRPV1, immunohistochemical stud-
ies were performed. Nuclear labelling with DAPI showed
that TRPV1 and MOP antibodies only labelled cells with
neuronal morphology, while many cells showing DAPI
labelling, presumably accessory cell types such as glia and
astrocytes, remained unlabelled for TRPV1 and MOP (Fig-
Inhibition of FSK-stimulated cAMP accumulation by mor- phine (1 μM) Figure 3
Inhibition of FSK-stimulated cAMP accumulation by mor-
phine (1 μM). cAMP levels in FLAG-MOP/TRPV1 double sta-
ble colonies were measured using an enzyme-immunoassay 
kit either in unstimulated cells (no FSK), or in cells treated 
with FSK (50 μM) and IBMX (100 μM). Morphine (1 μM) sig-
nificantly reduced cAMP levels in FSK-stimulated cells (mor-
phine) compared to stimulated cells treated with water 
(vehicle). Morphine inhibited cAMP production by 67.0 ± 
4.6% for FLAG-MOP/TRPV1 colony 13 (dotted bars) and 
79.2 ± 7.4% for colony 21 (cross-hatched bars). Data are 
presented as mean ± SEM from n = 3 samples read in tripli-
cate. ** p < 0.01 compared to vehicle.Molecular Pain 2006, 2:22 http://www.molecularpain.com/content/2/1/22
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ure 8A–C). Staining patterns for TRPV1 and MOP were in
accordance with published literature [25-28].
Of the 173 cultured DRG neurones which represented the
subset of neurons that were labelled for TRPV1 and MOP,
88.4% were co-labelled for TRPV1 (Figure 8C, red) and
MOP (Figure 8B, green) with the overlay (yellow) clearly
showing co-expression of the receptors, although the level
of expression was somewhat variable between cells.
Eleven neurones (6.4%) were labelled for TRPV1 only,
while a further 9 neurones (5.2%) expressed only MOP.
Discussion
The results reported in this study provide the first evidence
for a functional interaction between the MOP and the
TRPV1 and indicate that this interaction likely occurs via
modulation of PKA-augmented TRPV1 responses. These
results may have implications in inflammatory pain.
For both the MOP and TRPV1, transfected HEK-293 cells
are a widely used model for assessing receptor functions as
well as interactions with other receptors [12,16,28-31].
Using a heterologous expression system, we showed that
morphine does not inhibit capsaicin-induced TRPV1
responses under basal conditions. However, morphine
inhibits FSK-potentiated TRPV1 responses through action
at the MOP receptor, as indicated by reversal with the opi-
oid receptor antagonist naloxone. This inhibition is likely
dependent upon modulation of cAMP-dependent PKA, as
morphine does not affect capsaicin responses potentiated
by the direct PKA activator 8-Br-cAMP or the PKC activator
PMA.
FSK potentiates capsaicin-induced Ca2+ responses in FLAG-MOP/TRPV1 double stable HEK293 cells Figure 4
FSK potentiates capsaicin-induced Ca2+ responses in FLAG-MOP/TRPV1 double stable HEK293 cells. Pre-incubation with vary-
ing concentrations of FSK (0.5–500 μM) and constant concentrations of IBMX (100 μM) caused a FSK-concentration-depend-
ent increase in Ca2+ response to the injection of 300 nM capsaicin in colony 21 ((A)) and colony 13 (■, (C)). (B and D) 
Individual Ca2+ traces after injection of 300 nM capsaicin from Fluo-3-loaded double colonies (Colony 21, (B) and Colony 13, 
(D)). Cells responded with a characteristic increase in intracellular Ca2+ after injection of capsaicin, which was increased after 
15 minutes incubation with FSK and IBMX (100 μM). Data are presented as mean ± SEM with n = 4.Molecular Pain 2006, 2:22 http://www.molecularpain.com/content/2/1/22
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The antinociceptive actions of opioids are more effica-
cious in inflammation; and MOP as well as TRPV1 expres-
sion are increased in inflamed tissues, along with
increased cAMP levels in these tissues [9,32,33]. While
binding affinities of MOP agonists remain unchanged, the
efficacy of G-protein coupling is increased during inflam-
mation [34]. In addition, opioid receptor expression is
markedly upregulated as early as one day after induction
of inflammation, and this increase in expression is paral-
leled by an increase in inhibition of neuronal Ca2+
responses [34,35]. Due to disruption of the perineurium
in inflammation, opioids have improved access to periph-
Morphine inhibits FSK-potentiated capsaicin responses in FLAG-MOP/TRPV1 double stable HEK293 cells but not capsaicin  responses in absence of FSK Figure 5
Morphine inhibits FSK-potentiated capsaicin responses in FLAG-MOP/TRPV1 double stable HEK293 cells but not capsaicin 
responses in absence of FSK. Double stable FLAG-MOP/TRPV1 colonies were loaded with Fluo-3 and pre-incubated with PSS 
for untreated or morphine (1 μM) for treated cells for 15 min followed by further incubation with buffer containing either no 
added drugs for unstimulated cells or FSK (50 μM) and IBMX (100 μM) stimulated cells. Ca2+ responses after injection of cap-
saicin were monitored for 45 s using a fluorescent microplate reader. (A and D) Capsaicin dose-response curves for colony 21 
(A) and colony 13 (D) without pre-treatment (capsaicin, ▼), after morphine incubation (capsaicin+morphine, x), after pre-
incubation with FSK+IBMX (capsaicin+FSK+IBMX, ●) and after treatment with FSK, IBMX and morphine (capsai-
cin+FSK+IBMX+morphine, ). A 4-parameter Hill equation was fitted using GraphPad Prism. Data was plotted as maximum 
increase in fluorescence (ΔF/F) after injection of capsaicin. FSK-potentiated capsaicin responses were inhibited by morphine (1 
μM), while capsaicin responses in the absence of FSK were not affected by morphine. B and C, E and F: Representative Ca2+ 
responses evoked by capsaicin (300 nM) in FLAG-MOP/TRPV1 expressant 21 (B and C) and 13 (E and F). FLAG-MOP/TRPV1 
colony 21 and 13 responded to injection with 300 nM capsaicin with a characteristic increase in Ca2+, represented as an 
increase in ΔF/F (B and E). Pre-incubation with morphine (1 μM) did not affect the magnitude of Ca2+ responses (B and E). 
Pre-incubation with FSK (50 μM) and IBMX (100 μM) increased capsaicin-evoked Ca2+ responses (C and F) and treatment with 
morphine (1 μM) inhibited FSK-potentiated capsaicin responses (C and F). Data are presented as mean ± SEM with n = 8 for 
each colony and capsaicin concentration and statistical significance were determined at peak Ca2+ responses after addition of 
capsaicin. * p < 0.05 compared to FSK alone.Molecular Pain 2006, 2:22 http://www.molecularpain.com/content/2/1/22
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(A) Naloxone reverses morphine-inhibition of FSK-potentiated TRPV1 Ca2+ responses Figure 6
(A) Naloxone reverses morphine-inhibition of FSK-potentiated TRPV1 Ca2+ responses. Fluo-3 loaded FLAG-MOP/TRPV1 dou-
ble expressants (Colony 21) were pre-incubated with PSS for untreated cells (*) or morphine (1 μM) and naloxone (50 μM) as 
appropriate for treated cells for 15 min, followed by incubation with PSS for unstimulated cells or FSK (50 μM) and IBMX (100 
μM) for stimulated cells. Pre-treatment with the opioid receptor antagonist naloxone (50 μM) () prevented inhibition of FSK-
potentiated capsaicin (300 nM) responses (●) by morphine (x). (B) Pre-incubation with morphine and activation of second 
messenger systems is required for morphine-inhibition of FSK-potentiated capsaicin responses. Fluo-3 loaded FLAG-MOP/
TRPV1 double expressants (Colony 21) were pre-incubated with PSS for unstimulated cells (*) or FSK (50 μM) and IBMX (100 
μM) for stimulated cells. Injection of morphine () to a well concentration of 1 μM alongside capsaicin (300 nM) did not affect 
capsaicin (300 nM) responses in FSK-stimulated cells (●). Data are presented as mean ± SEM for n = 8 and statistical signifi-
cance was determined at peak Ca2+ responses after addition of capsaicin. * p < 0.05 for FSK+morphine compared to FSK alone.Molecular Pain 2006, 2:22 http://www.molecularpain.com/content/2/1/22
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8-Br-cAMP stimulated capsaicin responses are not inhibited by morphine Figure 7
8-Br-cAMP stimulated capsaicin responses are not inhibited by morphine. (A) FLAG-MOP/TRPV1 double stable HEK293 cells 
(Colony 21) were loaded with the fluorescent Ca2+ dye Fluo-3 and Ca2+ responses to injection of 300 nM capsaicin were mon-
itored using a fluorescent Microplate reader. Cells were pre-incubated for 15 min with IBMX (100 μM) as well as varying con-
centrations of the direct PKA activator 8-Br-cAMP (1 mM, 300 μM, 100 μM, 30 μM, 10 μM, 3 μM, 1 μM or PSS). Capsaicin 
(300 nM) was injected and Ca2+ responses plotted as the maximum increase in ΔF/F after capsaicin injection. Pre-incubation 
with 8-Br-cAMP and IBMX potentiated Ca2+ responses to 300 nM capsaicin in an 8-Br-cAMP-concentration-dependent man-
ner. (B) Morphine does not inhibit capsaicin responses potentiated by the direct PKA activator 8-Br-cAMP. Fluo-3 loaded 
FLAG-MOP/TRPV1 cells were incubated with PSS for untreated cell () or morphine (1 μM) for treated cells (❍) for 15 min, 
followed by potentiated with IBMX (100 μM) and 8-Br-cAMP (300 μM) for 15 min. Untreated control responses are denoted 
by (*). Pre-incubation with morphine did not inhibit 8-Br-cAMP potentiated capsaicin responses (❍). Data are presented as 
mean ± SEM for n = 4–8. (C) Morphine does not inhibit capsaicin responses potentiated by the PKC activator PMA. Fluo-3 
loaded FLAG-MOP/TRPV1 cells were incubated with PSS for untreated cell (*). PMA-potentiation was achieved by incubation 
of cells for 10 minutes with PMA (100 nM), preceded by 15 min incubation with PSS for control responses (❍) or morphine (1 
μM) for treated cells (▼). Pre-incubation with morphine did not inhibit 8-Br-cAMP potentiated capsaicin responses.Molecular Pain 2006, 2:22 http://www.molecularpain.com/content/2/1/22
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eral nerve endings on these inflamed tissues [36]. These
changes highlight not only the importance of inflamma-
tory sensitization in altering nociceptive receptor function
but also the importance of sensitization in possibly
increasing the ability of MOP to inhibit these sensitized
inflammatory nociceptive responses. However, molecular
pathways involved in this increased efficacy of opioids in
inflammation have not been systematically assessed to
date.
In peripheral sites of inflammation, opioids have been
shown to inhibit neurogenic inflammation by decreasing
the release of substance P from peripheral afferent termi-
nals [37]. Notably, activation of the TRPV1 causes SP
release and neurogenic inflammation [38] and opioids
have been shown to inhibit capsaicin-evoked substance P
release [39].
The specific MOP agonist endomorphine as well as the
clinically useful MOP agonist morphine have been shown
to produce anti-inflammatory effects in animal models
and human studies when injected directly into inflamed
tissues [40-44]. Importantly, activation of the TRPV1 by
capsaicin induces hyperalgesia that can, dose-depend-
ently and in a naloxone-sensitive manner, be inhibited by
peripherally applied μ- and κ-opioid agonists [45-47],
although the mechanisms involved in opioid-inhibition
of TRPV1 responses have not been elucidated to date. Our
results present a novel molecular basis for the anti-inflam-
matory action of peripheral opioids through a functional
interaction of the MOP and PKA-sensitized TRPV1.
Several receptors have been reported to functionally inter-
act with the TRPV1 [6,12,16,17,28,48]. Most of these
receptors effect potentiation of TRPV1 responses through
activation of second messenger systems, resulting in acti-
vation of PKC and cAMP-dependent PKA pathways
[6,12,16,17,28,48]. Specifically, Insulin Growth Factor-1,
insulin, bradykinin, nerve growth factor and prostagland-
ins can sensitize the TRPV1 through PKC-mediated phos-
phorylation, while PKA is involved in PGE2- and
anandamide-mediated TRPV1 sensitization as well as
potentiation of capsaicin responses through the metabo-
tropic glutamate receptor 5 [6,16,17,28,48]. The PKA
pathway has been proposed to be involved in the develop-
ment of inflammatory hyperalgesia [9,11]. cAMP levels
are elevated in inflamed tissues [9,10] and PKA or ade-
nylate cyclase activators lower nociceptive thresholds
while PKA inhibitors can be anti-hyperalgesic [49]. The
cAMP/PKA pathway appears to be essential in sensitizing
inflammatory nociception and contributes to the devel-
opment of inflammatory hyperalgesia induced by proin-
flammatory mediators such as prostaglandin E2 (PGE2)
[9,11].
Activation of peripheral group II metabotropic glutamate
receptors inhibits potentiation of capsaicin responses by
both PGE2 and FSK, but not potentiation by the direct
PKA activator 8-Br-cAMP [14], consistent with our find-
ings with MOP inhibiting TRPV1 in the presence of FSK.
Although there are no previous studies of opioid receptors
altering PKA-sensitization of capsaicin responses, the G-
protein coupled cannabinoid receptor 1 (CB1) inhibits
FSK-potentiated capsaicin responses in a PKA-dependent
manner [12,50]. Importantly, while anandamide and
other CB1 agonist can directly activate the TRPV1 under
basal conditions and cause TRPV1-mediated Ca2+ influx
[12,50], our results showed that opioids did not affect
capsaicin-induced TRPV1 responses under basal condi-
tions. Our results suggest that activation of opioid recep-
Cultured Dorsal Root Ganglion Neurones co-express TRPV1 and MOP Figure 8
Cultured Dorsal Root Ganglion Neurones co-express TRPV1 and MOP. (A) DAPI stain (blue) shows cell nuclei of neurones as 
well as accessory cells. (B) Labelling with anti-MOP antibody, visualised with a FITC-conjugated secondary antibody, shows 
expression of MOP protein in cells with neuronal morphology, but not accessory cells. (C) TRPV1 protein (red) was visualised 
using a TRPV1 antibody with Cy3-conjugated secondary antibody. (D) Overlay of panels A, B and C shows co-expression of 
TRPV1 and MOP (yellow) in cultured DRG neurones. Scale bar = 12 μm.Molecular Pain 2006, 2:22 http://www.molecularpain.com/content/2/1/22
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tors could be utilized to prevent sensitization of TRPV1
receptors by cAMP-dependent PKA in inflammation with-
out the potential to activate unpotentiated TRPV1.
Activation of opioid receptors decreases cAMP levels and
inhibition of NMDA currents by opioids occurs in a PKA-
dependent manner through inhibition of adenylate
cyclase [51]. Opioid modulation of TRPV1 responses may
thus occur in inflamed tissues, where cAMP levels are ele-
vated [11] through inhibition of adenylate cyclase and a
subsequent inhibition of potentiation of TRPV1 responses
by cAMP-dependent PKA. The results presented here sup-
port the hypothesis that the MOP and TRPV1 can func-
tionally interact through a cAMP-dependent PKA
pathway, as morphine inhibited FSK-potentiated capsai-
cin responses but not capsaicin responses in the absence
of FSK. This is the first demonstration of a functional
interaction between the TRPV1 and the MOP at the
molecular level, and the interaction demonstrated here
may be of significance in the treatment of inflammatory
pain. In inflammation, when signalling through the
TRPV1 is enhanced through increased PKA activity, activa-
tion of peripheral MOP could be utilised to prevent or
modify TRPV1 sensitization. Moreover, while PKA path-
ways have been recognised to contribute to the develop-
ment of inflammatory hyperalgesia, PKC pathways and in
particular PKC-mediated phosphorylation have been pos-
tulated to contribute to the development of neuropathic
hyperalgesia and allodynia [24,52]. We did not observe
morphine modulation of PKC-potentiated TRPV1
responses; thus, the differential involvement of PKA and
PKC in neuropathic and inflammatory pain may provide
a mechanistic explanation for the predominant efficacy of
morphine in inflammatory but not neuropathic pain
states.
The time-dependency of morphine-inhibition of FSK-
potentiated capsaicin responses supports the notion that,
via activation of the MOP, and subsequent negative cou-
pling to adenylate cyclase through G proteins [51], mor-
phine can prevent sensitization of capsaicin responses
through the cAMP/PKA pathway. cAMP assays performed
on our FLAG-MOP/TRPV1 cell line showed that while
incubation with morphine significantly reduced FSK-
stimulated cAMP production, morphine at the concentra-
tions used here, did not reverse cAMP levels to unstimu-
lated levels. Accordingly, morphine did not completely
inhibit FSK-potentiation of TRPV1-mediated Ca2+
responses.
To rule out the possibility that morphine modulates FSK-
potentiated capsaicin responses through action on phos-
phodiesterase or PKA and other downstream effectors, we
used 8-Br-cAMP, a direct PKA activator, to potentiate cap-
saicin responses. While 8-Br-cAMP potentiated capsaicin
responses similar to FSK, morphine did not modulate cap-
saicin responses potentiated by 8-Br-cAMP.
As the MOP is coupled negatively to adenylate cyclase and
thus indirectly to PKA [18,51], direct activation of PKA
and thus potentiation of capsaicin responses would
negate the inhibitory effect of opioids on adenylate
cyclase. These results indicate that morphine modulates
FSK-potentiated capsaicin responses by inhibiting ade-
nylate cyclase.
Several studies show expression of the TRPV1 and MOP
on peripheral neurones as well as DRG [53,54]. More spe-
cifically, expression of TRPV1 has been reported in a small
subset of trk-A and IB4-positive DRG neurons [1,2,55]. In
addition, the number of TRPV1-expressing neurons
increased after inflammation [3], with NGF reportedly
regulating TRPV1 expression in trk-A-positive neurons
[55].
While the DRG culture conditions utilised in our study
included NGF and may therefore represent increased
expression of TRPV1 in trk-A-expressing fibres, our find-
ings are nonetheless relevant as increased NGF levels
occur physiologically during inflammation [55]. Our
finding of significant co-expression of TRPV1 and MOP in
cultured DRG neurons was further confirmed in a recently
published study assessing TRPV1 and MOP expression in
both L4 and L5 dorsal root ganglia as well as lumbar spi-
nal cord of rats [56]. While the proportion of neurons
expressing TRPV1 and MOP was not quantified, similar to
our results most neurons appeared to co-express TRPV1
and MOP with only relatively few cells expressing only
one of the two receptors [56]. In addition, comparable to
the percentage of neurons co-expressing TRPV1 and MOP
in our study, Sanderson Nydahl et al reported 83% of L4
and L5 DRGs to co-express the MOP agonist endomor-
phin and TRPV1 [57], This co-expression of TRPV1 and
MOP in the majority cultured DRG neurones may provide
the anatomical basis for functional interaction of the
nociceptive TRPV1 and antinociceptive MOP receptors,
thus allowing for local regulation and subsequent modifi-
cation of nociception.
However, inhibition of capsaicin-induced hyperalgesia in
vivo could rely not only on PKA mediated pathways but
may also include inhibition of Ca2+ channels or the inhi-
bition of substance P release [39].
Conclusion
Our studies demonstrate for the first time that in a heter-
ologous expression system where MOP and TRPV1 are sta-
bly co-expressed, morphine can inhibit capsaicin
responses when the cAMP pathway is activated and this
occurs through opioid-modulation of adenylate cyclaseMolecular Pain 2006, 2:22 http://www.molecularpain.com/content/2/1/22
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and thus indirectly PKA-mediated TRPV1 sensitization. As
TRPV1 is expressed peripherally [3,4] and PKA-mediated
sensitization occurs in these peripheral nociceptors via
inflammatory mediators [9], targeting of non-central opi-
oid receptors in inflammatory conditions may prevent
peripheral sensitization and thus contribute to analgesia.
Moreover, increased MOP expression and function during
inflammation may contribute to local regulation of sensi-
tization of nociceptors. This interaction may present the
molecular basis for endogenous anti-inflammatory effects
of opioids.
Materials and methods
Materials
Capsaicin and capsazepine were purchased from Sigma
Aldrich (Castle Hill, NSW, Australia) and prepared as
stock solutions in ethanol. Maximum final ethanol con-
centrations did not exceed 0.001%. 3-Isobutyl-1-methyl-
xanthine (IBMX), forskolin (FSK), 8-bromo-adenosine
3',5'-cyclic monophosphate (8-Br-cAMP) and Phorbol 12-
myristate 13-acetate(PMA) were from Sigma Aldrich and
prepared as stocks in 100% dimethylsulfoxide (DMSO),
with maximum DMSO concentrations not exceeding
0.1%. Morphine was obtained from David Bull Laborato-
ries (Mulgrave, Victoria, Australia) and diluted in physio-
logical salt solution (PSS). Geneticin and hygromycin
selection antibiotics were from Invitrogen (Mulgrave, Vic-
toria, Australia). QIAEX II agarose gel extraction kit was
purchased from Qiagen (Doncaster, Victoria, Australia).
Polyclonal rabbit anti-FLAG M2 antibody was purchased
from Sigma. Polyclonal guinea-pig anti-MOP and poly-
clonal rabbit anti-TRPV1 antibodies were from Chemicon
(Boronia, Victoria, Australia). Cy3-conjugated goat anti-
mouse antibody was from Zymed Laboratories (San Fran-
cisco, CA) and FITC-conjugated goat anti-guinea pig as
well as FITC-conjugated anti-mouse antibodies were pur-
chased from Sigma. Slow-Fade Antifade was from Molec-
ular Probes (Eugene, OR). Lipofectamine 2000 was
purchased from Invitrogen (Mulgrave, Victoria, Aus-
tralia). Protein estimation kit and Mini Trans-Blot® Elec-
trophoretic Transfer Cell were purchased from Bio-Rad
(Hercules, CA). Enhanced chemiluminescence Plus (ECL
Plus) was obtained from Amersham Biosciences (Buck-
inghamshire, England), and cAMP kits were supplied by
Cayman Chemicals (Ann Arbor, MI). All other chemicals
were purchased from Sigma.
Construction of the pcDNA3.1 Hygro(+)-TRPV1 plasmid
The pcDNA3 plasmid containing the cDNA of the rat
TRPV1 was a kind gift from David Julius (University of
California, San Francisco) [1]. The TRPV1 sequence was
released from the pcDNA3 plasmid using KpnI and XbaI,
isolated with QIAEX II agarose gel extraction kit and sub-
cloned into the plasmid pcDNA3.1 Hygro (+) (Invitro-
gen), which contains a hygromycin resistance sequence,
using the corresponding KpnI and XbaI sites. The nucleo-
tide sequence of the subcloned TRPV1 was compared
against GeneBank.
Generation of a HEK293 cell line stably expressing MOP 
and TRPV1
A plasmid containing the cDNA encoding the murine
FLAG-epitope-tagged μ opioid receptor (FLAG-MOP) as
well as a geneticin-resistance gene was a generous gift
from Dr Selena Bartlett (Ernest Gallo Clinic and Research
Centre, San Francisco, California).
In brief, HEK293 cells were transfected with pcDNA3 con-
taining FLAG-MOP using Lipofectamine 2000 (Invitro-
gen) according to the manufacturer's protocol and stable
FLAG-MOP expressants were selected with geneticin (0.5
mg/ml). Colonies originating from a single cell were
selected and FLAG-MOP expression verified using immu-
nohistochemistry and Western Blotting and a single clone
was selected for transfection of the TRPV1. In a similar
manner the pcDNA3.1 Hygro (+)/TRPV1 was transfected
into the stable FLAG-MOP expressant. In order to select
cells stably expressing functional TRPV1, cells were
selected using hygromycin (75 μg/ml) and colonies of
approximately 500 cells were isolated, plated on 96 well
plates and further screened for functional TRPV1 expres-
sion by measuring Ca2+ responses after injection of capsa-
icin (10 μM). TRPV1 expression was verified by Western
blotting. Double stable FLAG-MOP/TRPV1 expressants
were split every 4–6 days using trypsin/EDTA and main-
tained at 37°C in a 5% humidified CO2 incubator in Dul-
becco's modified Eagle's medium (DMEM) containing
10% heat-inactivated foetal bovine serum (FBS), 2 mM L-
glutamine, pyridoxine and 110 mg/ml sodium pyruvate
supplemented with geneticin (0.2 mg/ml) and hygromy-
cin (50 μg/ml).
SDS-PAGE and Western Blotting
For detection of MOP and TRPV1 receptor proteins, stable
FLAG-MOP/TRPV1 double expressants were plated on 10
cm dishes and grown to confluency before sample prepa-
ration with ice cold lysis buffer (NaCl 100 mM; Igepal 1%,
Na deoxycholate 0.5%; Tris pH 8.0 50 mM) containing
complete protease inhibitor mix (Roche, Castle Hill,
NSW). Cells were removed from the culture dish with lysis
buffer, homogenised by vortexing and incubated for 20
min on ice. After centrifugation at 6000 × g at 4°C for 20
min, protein estimation of the supernatant was performed
according to manufacturer's instructions using a protein
estimation kit (BioRad). Protein (20 μg) was precipitated
by boiling at 90°C for 2 min and separated on a 7.5% SDS
PAGE gel. Proteins were transferred to nitrocellulose
membrane and blocked overnight at 4°C in blocking
buffer (130 mM NaCl, 2.7 mM KCl, 10 mM NaH2PO4, 1.8
mM KH2PO4, 0.1% Tween-20 and 5% low-fat skim milkMolecular Pain 2006, 2:22 http://www.molecularpain.com/content/2/1/22
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powder), followed by incubation for 1 h with anti-TRPV1
antibody (1:1000) for detection of TRPV1 protein or anti-
FLAG M2 antibody (1:330) for detection of FLAG-MOP
protein. For TRPV1 immunoblots, an anti-β-actin anti-
body (1:10 000) was also included for visualisation of β-
actin to serve as a loading control (Data not shown). After
a wash with blocking buffer, blots were incubated with
appropriate secondary horseradish peroxidase (hrp)-con-
jugated antibody (1:5000; Zymed) in blocking buffer for
1 h and processed using ECL Plus for visualization by
exposure to Eastman Kodak XAR film.
cAMP accumulation assay
For the cAMP accumulation assay, FLAG-MOP/TRPV1
double expressants were plated on 12 well plates and
grown to 90% confluency. Twenty-four hours prior to
sample preparation, media was changed to DMEM sup-
plemented with 0.5% heat-inactivated FBS. On the day of
sample preparation, cells were washed with DMEM to
remove serum and incubated with serum-free DMEM con-
taining the phosphodiesterase inhibitor IBMX (100 μM)
for 30 min, to which morphine (1 μM) was then added
and cells incubated for a further 15 min. Following this,
FSK (50 μM) was added to the wells and the cells incu-
bated for 15 min to stimulate cAMP production. DMSO
alone was used as a vehicle control. After incubation, reac-
tions were terminated by aspiration of the medium and
addition of 0.1 M HCl followed by 20 min incubation at
room temperature. After centrifugation of the cell samples
at 10,000 × g for 10 min, the protein content of the super-
natant was assessed and the samples were diluted to pro-
tein concentrations of 20 μg/ml using enzyme
immunoassay (EIA) buffer supplied with the cAMP EIA
kit. Intracellular cAMP levels were measured with a com-
petitive cAMP EIA kit in triplicate as per manufacturer's
instructions.
Microplate reader measurement of intracellular Ca2+ 
responses in FLAG-MOP/TRPV1 HEK293 cells
Ca2+ responses of FLAG-MOP/TRPV1 HEK293 cells were
assessed using the fluorescent Ca2+ probe Fluo-3. FLAG-
MOP/TRPV1 expressants were plated on poly-D-lysine
(PDL)-coated 96-well plates at a cell density of approxi-
mately 3–4 × 105 cells/ml 3 to 5 days prior to experiments
and used at 70–90% confluency. Cells were loaded with
Fluo-3 AM (6 μM) in loading buffer (pH 7.4, composition
as PSS plus 3 mg/ml bovine serum albumin (BSA)) for
20–30 min at 37°C. Wells containing FLAG-MOP/TRPV1
double expressants were then washed three times with
PSS (pH 7.4, composition KCl 5.9 mM, MgCl2 1.5 mM,
NaH2PO4 1.2 mM, NaHCO3 5.0 mM, NaCl 140.0 mM,
Glucose 11.5 mM, CaCl2 1.8 mM and HEPES 10.0 mM)
and incubated for 15 min with PSS or opioid followed by
15 min of incubation with PSS or kinase activators with
opioid as appropriate. Pre-incubation steps and Ca2+
imaging was carried out at 29°C in order to avoid subcel-
lular dye compartmentalization while maintaining con-
stant experimental conditions. Capsaicin and other drugs
were injected from a 10 × concentrated stock in order to
achieve the required well concentration.
Fluo-3 loaded cells were excited at 420 nm and emission
was recorded at 510 nm using a NOVOstar fluorescence
microplate reader (BMG Victoria, Australia). Fluorescent
emission readings were recorded every 0.5 s. Raw fluores-
cence data were corrected by subtracting the average fluo-
rescence from 4 recordings just prior to addition of
agonist from all subsequent time points. This value was
then divided by the average fluorescence prior to addition
of agonist to yield ΔF/F values [58-60]. For dose-response
curves, maximum ΔF/F values from the response after
addition of agonist were plotted against agonist concen-
tration and a 4-parameter logistic Hill equation was fitted
to the data using GraphPad Prism (San Diego, California).
IBMX (100 μM) was contained in all experiments utilizing
FSK and 8-Br-cAMP as well as in appropriate controls to
exclude any effect of morphine on IBMX. All experiments
were designed to include control experiments on the same
plate as treated cells.
Dorsal Root Ganglion (DRG) cell culture
DRGs were collected from adult male Wistar rats (200–
350 g). The animals were kept in a controlled environ-
ment at a temperature of 22 ± 0.5°C, relative humidity of
40–60% and a 12 h (6 am–6 pm) light-dark cycle with
free access to standard lab chow and tap water. Animals
were sedated by inhalation of 50% O2/50% CO2 and sac-
rificed by asphyxiation with 100% CO2. DRGs were col-
lected from the rat spinal cord under sterile conditions
from level T12 to S2. Harvested DRGs were dissociated in
media containing trypsin (0.5 mg/ml), collagenase (1 mg/
ml) and DNAse (1 μg/ml) and incubated at 37°C and 5%
CO2 for 45 to 60 min. Trypsin-chymotrypsin inhibitor
(0.1 mg/ml) was then added and cell suspension centri-
fuged at 200 rpm for 10 min. The cell pellet was resus-
pended in 2 ml of warm medium consisting of DMEM
supplemented with glutamine (4 mM), 10% horseserum,
10% foetal bovine serum, penicillin streptomycin (2 mM)
and NGF (nerve growth factor) (100 ng/ml). Cells were
plated on 25 mm PDL-coated glass coverslips at a density
of 75,000 to 200,000 cells per coverslip. After 1 h, the
medium was changed to Neurobasal-A medium supple-
mented with glutamine (4 mM), NGF (100 ng/ml) and
B27 (20 μl/ml). Media was replaced every 2 days and
experiments were performed after 3–6 days in culture.
Cell cultures were confirmed visually to have characteris-
tic DRG neuronal morphology combined with positive
staining for synaptophysin.Molecular Pain 2006, 2:22 http://www.molecularpain.com/content/2/1/22
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TRPV1 and MOP receptor immunoreactivity in cultured 
DRG neurones and FLAG-MOP/TRPV1 transfected 
HEK293 cells
Cells plated on 25 mm coverslips were washed twice in
PBS (mM: NaCl 137; KCl 2.7; NaH2PO4 10; KH2PO4 1.8)
for 10 min before being fixed with 4% paraformaldehyde
for 20–30 min at room temperature. Cells were permeabi-
lized with 0.2% Triton X in PBS for 10 min and blocked
by immersion in PBS with 3% BSA for 30 min. Cells were
washed thoroughly with PBS between all incubation
steps. All antibodies were prepared in PBS containing 3%
BSA. For DRG neurones, guinea pig anti-MOP primary
antibody (1:5000) was applied for 1 h, while for FLAG-
MOP/TRPV1 transfected HEK cells, mouse anti-FLAG M2
primary antibody (1:500) was applied for 1 h, followed
by FITC-labelled anti-guinea pig or FITC-labelled anti-
mouse secondary antibody (1:300) as appropriate in low
light for 30 min. Cells were then incubated with rabbit
anti-rat TRPV1 primary antibody (1:4000) for 1 h, fol-
lowed by incubation with anti-rabbit Cy3-conjugated sec-
ondary antibody (1:300) under low light for 30 min.
Subsequent incubation of coverslips with 4',6-diamidino-
2-phenylindole dihydrochloride (DAPI; 300 nM) for 1–5
min was utilized to visualize cellular DNA. Specificity of
the TRPV1 antibody was previously demonstrated [54]
and confirmed here through lack of non-specific binding
in cultured DRG neurones as well as double stable
HEK293 cells (Figure 1F and 1G). Specificity of the MOP
antibody was demonstrated by dual labelling of stable
FLAG-MOP expressants with anti-MOP and anti-FLAG M2
antibodies, which showed excellent overlay (data not
shown). Cells were thoroughly rinsed with PBS and dis-
tilled water and mounted using SlowFade AntiFade before
viewing randomly selected fields of view on a Nikon
Eclipse TE 300 inverted fluorescent microscope (excita-
tion 488 nm, emission 520 nm for FITC; excitation 540
nm, emission 570 nm for Cy3 and excitation 364 nm,
emission 454 nm for DAPI). Pictures were recorded using
MetaFluor (Molecular Devices, Downington, PA) imaging
software and processed using Paintshop Pro for Windows
(Microsoft).
Data analysis
Data are presented as mean ± standard error of the mean
(SEM) of at least two to three independent experiments.
Fitting of 4-parameter Hill equations and statistical analy-
sis were carried out using GraphPad Prism Version 4 (San
Diego, CA). Statistical significance was determined using
an unpaired, two-tailed Student's t-test unless otherwise
stated with statistical significance defined as p < 0.05.
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